Dendrite to Present at Bear Stearns 19th Annual Healthcare Conference; September 11, 2006 at the Grand Hyatt in New York City
September 06 2006 - 3:43PM
Business Wire
Executives from Dendrite International, Inc. (NASDAQ: DRTE) will be
speaking at the Bear Stearns 19th Annual Healthcare Conference,
which will be held September 11-12, 2006, at the Grand Hyatt in New
York City. The conference will feature presentations by companies
covering all sectors of the healthcare industry. On Monday,
September 11, 2006 at 11:30 am ET (Eastern Time), John Bailye,
Chairman and CEO and Jeffrey Bairstow, EVP and CFO will discuss
Dendrite's business and future growth opportunities. A link to a
live and replayed webcast will be available at www.dendrite.com in
the Investors Highlights section. About Dendrite Founded in 1986,
Dendrite International (NASDAQ: DRTE) enables sales, marketing,
clinical and compliance solutions for the global pharmaceutical
industry. The Company's clients are located in more than 50
countries and include the world's top 20 pharmaceutical companies.
For more information, please visit www.dendrite.com. For more
information on OPUS Health, please visit www.opushealth.com. Note:
Dendrite is a registered trademark of Dendrite International, Inc.
This document may contain forward-looking statements that may be
identified by such forward-looking terminology as "expect,"
"believe," "anticipate," "will," "intend," "plan," "target,"
"outlook," "guidance," and similar statements or variations. Such
forward-looking statements are based on our current expectations,
estimates, assumptions and projections and involve significant
risks and uncertainties, including risks which may result from our
dependence on the pharmaceutical industry; our fixed expenses in
relation to fluctuating revenues and variations in customers'
budget cycles; dependence on certain major customers, including the
risk associated with one substantial customer currently assessing
its U.S. sales force effectiveness services needs; our ability to
successfully implement our Operational Effectiveness program and to
achieve the cost savings in the amounts and time periods expected
or budgeted; changes in demand for our products and services
attributable to any weakness experienced in the economy or mergers,
acquisitions and consolidations in the pharmaceutical industry;
risks associated with foreign currency fluctuations and our ability
to adapt and respond successfully to other unique risks involved in
our non-U.S. operations; integrating the entities we acquire; and
our ability to effectively manage our growth. Other important
factors that should be reviewed and carefully considered are
included in the company's 10-K, 10-Qs, and other reports filed with
the SEC. Actual results may differ materially. The company assumes
no obligation for updating any such forward-looking statements to
reflect actual results, changes in assumptions or other changes
affecting such forward-looking statements and the information
provided in this press release should not be construed as updating,
modifying or confirming the company's most recent financial outlook
or guidance.
Dendrite (NASDAQ:DRTE)
Historical Stock Chart
From Jul 2024 to Aug 2024
Dendrite (NASDAQ:DRTE)
Historical Stock Chart
From Aug 2023 to Aug 2024